Other Clinical Trial - Clinical Utility of VI-RADS in Diagnosis of MIBC

Status Active, not recruiting

Clinical Trial Summary

Bladder Cancer (BCa) is the 9th most common cancer worldwide. In general, BCa is presented as a non-muscle invasive bladder cancer (NMIBC) in 70% of patients and treated with transurethral resection of bladder tumor (TUR-BT). However, in cases of muscle invasive bladder cancer (MIBC), radical cystectomy (RC) is the gold standard of treatment. Therefore, It is important to distinguish MIBC from NMIBC. To date, pathologic staging is based on the result of TUR-BT before RC. However, it is operator dependent, thus residual cancer may be remained depending on surgical experience. Therefore, about 7%-30% patients of MIBC can be underestimated with NMIBC, and it can be increased to 45% if the muscle is not resected. Consequently, it has been raised the need for imaging test to overcome diagnostic limitations. Multiparametric magnetic resonance imaging (mpMRI) has been widely used in the field of diagnosis of BCa. In 2018, the Vesical Imaging Report and Data System (VI-RADS) was published using T2-weighted imaging (T2WI), diffusion-weighted imaging (DWI), and dynamic contrast enhanced (DCE) imaging, and 5-point VI-RADS scoring system has been proposed and reported as an imaging test useful for assessing muscle involvement in primary bladder cancer Therefore, in this study, we investigate the diagnostic performance of the VI-RADS scoring system that can differentiate NMIBC from MIBC in primary bladder cancer.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05097404
Study type	Observational
Source	Samsung Medical Center
Contact
Status	Active, not recruiting
Phase
Start date	September 9, 2021
Completion date	September 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05483868` - A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer	Phase 1
Not yet recruiting	`NCT04966130` - Effect of Urinary Indwelling Time on Early Continence After Robot-assisted Radical Cystectomy With Orthotopic Ileal Neobladder.
Active, not recruiting	`NCT04610671` - Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC	Phase 1
Recruiting	`NCT06341400` - RC48 Combined With Toripalimab as Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients	Phase 1/Phase 2
Recruiting	`NCT06190197` - Prophylactic Antibiotics in Cystectomy With Diversion	Early Phase 1
Recruiting	`NCT05203913` - Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer	Phase 2
Recruiting	`NCT05790850` - Pre-Habilitation With Mindfulness and Exercise for Patients Undergoing Radical Cystectomy (PRIMER Trial)	N/A
Recruiting	`NCT05833867` - Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer	Phase 1
Recruiting	`NCT05295992` - Conventionally Fractionated Adaptive Radiation Therapy of Bladder Cancer an Individualized Approach	N/A
Recruiting	`NCT06215976` - The Nephroprotective Effect of Metformin With Cisplatin in Bladder Cancer	Phase 4
Recruiting	`NCT05028660` - AURORAX-0093A: Glycosaminoglycan Profiling for Prognostication of Muscle-invasive Bladder Cancer - a Pilot Study
Not yet recruiting	`NCT06417190` - Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology	Phase 2
Not yet recruiting	`NCT04909775` - Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer	Phase 2
Recruiting	`NCT04876313` - An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo)	Phase 2
Not yet recruiting	`NCT04686149` - a Genome-based Platform to Predict Patients That Can Achieve Bladder Preservation in Muscle Invasive Bladder Cancer Patients
Active, not recruiting	`NCT05630131` - ctDNA in Subjects With Muscle-invasive Bladder Cancer Treated With Trimodality Therapy
Recruiting	`NCT06170177` - Study on the Quality of Life and Pathological State in Patients Who Underwent Radical Cystectomy
Terminated	`NCT05221827` - Clinical Performance Evaluation of the C2i-Test
Recruiting	`NCT06257017` - Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma: A Pilot Randomized Controlled Trial	Phase 2
Recruiting	`NCT05767528` - Clinical Study of Neoadjuvant Therapy Outcome Prediction of Muscle-invasive Bladder Cancer Based on PTC Drug Sensitivity Detection